EMEA receives 24th report of PML case linked with Tysabri

There has been a recent surge in new confirmed cases of progressive multifocal leukoencephalopathy (PML) associated with the multiple sclerosis drug, Tysabri (natalizumab), with the 24th case reported to the EMEA on 25 October.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom